{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:39:32Z","timestamp":1787009972086,"version":"build-2736575974"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1097\/fjc.0b013e318160b42a","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T12:29:12Z","timestamp":1236256152000},"page":"217-222","source":"Crossref","is-referenced-by-count":35,"title":["Comparative Evaluation of Effect of Valsartan\/Amlodipine and Atenolol\/Amlodipine Combinations on Atrial Fibrillation Recurrence in Hypertensive Patients With Type 2 Diabetes Mellitus"],"prefix":"10.1097","volume":"51","author":[{"given":"Roberto","family":"Fogari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Zoppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amedeo","family":"Mugellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Corradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierangelo","family":"Lazzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Preti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Derosa","family":"MD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210208","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation inadults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial fibrillation (ATRIA) Study.","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"R2-1-20210208","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0002-9343(02)01236-6","article-title":"A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew\/Paisley study.","volume":"113","author":"Stewart","year":"2002","journal-title":"Am J Med"},{"key":"R3-1-20210208","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0002-9343(02)01253-6","article-title":"A population based study of mortality among patients with atrial fibrillation or flutter.","volume":"113","author":"Vidaillet","year":"2002","journal-title":"Am J Med"},{"key":"R4-1-20210208","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0002-9343(99)80348-9","article-title":"The natural history of atrial fibrillation: Incidence, risk factors and prognosis in the Manitoba Follow-up Study.","volume":"98","author":"Krahn","year":"1995","journal-title":"Am J Med"},{"key":"R5-1-20210208","doi-asserted-by":"crossref","first-page":"2N","DOI":"10.1016\/S0002-9149(98)00583-9","article-title":"Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: population-based estimates.","volume":"82","author":"Kannel","year":"1998","journal-title":"Am J Cardiol"},{"key":"R6-1-20210208","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1462-8902.2004.00358.x","article-title":"Atrial fibrillation and its association with type 2 diabetes mellitus and hypertension in a Swedish community.","volume":"6","author":"Ostgren","year":"2004","journal-title":"Diabetes Obes Metab"},{"key":"R7-1-20210208","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ijcard.2005.02.050","article-title":"Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease.","volume":"105","author":"Mohaved","year":"2005","journal-title":"Int J Cardiol"},{"key":"R8-1-20210208","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ijcard.2005.03.003","article-title":"Diabetes mellitus and atrial fibrillation: perspectives on epidemiological and pathophysiological links.","volume":"105","author":"Lip","year":"2005","journal-title":"Int J Cardiol"},{"key":"R9-1-20210208","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/dmrr.386","article-title":"Diabetic atrial fibrillation patients: mortality and risk for stroke or embolism during a 10-year follow-up.","volume":"19","author":"Klem","year":"2003","journal-title":"Diabetes Metab Res Rev"},{"key":"R10-1-20210208","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.2337\/diacare.21.9.1414","article-title":"Global burden of diabetes, 1995-2025: prevalence, numerical estimates and projections.","volume":"21","author":"King","year":"1998","journal-title":"Diabetes Care"},{"key":"R11-1-20210208","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1161\/01.CIR.0000121736.16643.11","article-title":"Relationships between sinus rhythm, treatment and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study.","volume":"109","author":"Corley","year":"2004","journal-title":"Circulation"},{"key":"R12-1-20210208","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1111\/j.1540-8167.1998.tb00114.x","article-title":"Atrial electrophysiological remodeling: another vicious circle?","volume":"9","author":"Allessie","year":"1998","journal-title":"J Cardiovasc Electrophysiol"},{"key":"R13-1-20210208","first-page":"21","article-title":"Mechanisms of atrial remodelling and clinical relevance.","volume":"20","author":"Nattel","year":"2005","journal-title":"Curr Opin Cardiol"},{"key":"R14-1-20210208","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1071-9164(05)80004-1","article-title":"Effects of lisinopril in patients with heart failure and chronic atrial fibrillation.","volume":"1","author":"Van der Berg","year":"1995","journal-title":"J Card Fail"},{"key":"R15-1-20210208","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1161\/01.CIR.100.4.376","article-title":"Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction.","volume":"100","author":"Pedersen","year":"1999","journal-title":"Circulation"},{"key":"R16-1-20210208","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1161\/01.CIR.0000072793.81076.D4","article-title":"Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction. Insights from the Studies Of Left Ventricular Dysfunction (SOLVD) Trials.","volume":"107","author":"Vermes","year":"2003","journal-title":"Circulation"},{"key":"R17-1-20210208","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/01.CIR.0000022665.18619.83","article-title":"Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. A prospective and randomized study.","volume":"106","author":"Madrid","year":"2002","journal-title":"Circulation"},{"key":"R18-1-20210208","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0140-6736(03)14183-9","article-title":"Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.","volume":"362","author":"Lindholm","year":"2003","journal-title":"Lancet"},{"key":"R19-1-20210208","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jacc.2004.10.068","article-title":"Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol. The Losartan Intervention For End-point reduction in hypertension (LIFE) Study.","volume":"45","author":"Wachtell","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R20-1-20210208","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ahj.2004.09.033","article-title":"Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).","volume":"149","author":"Maggioni","year":"2005","journal-title":"Am Heart J"},{"key":"R21-1-20210208","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1016\/j.jacc.2006.01.060","article-title":"Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular dysfunction: results from the Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity (CHARM) program.","volume":"47","author":"Olsson","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R22-1-20210208","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/01.fjc.0000193808.99773.28","article-title":"Losartan and prevention of atrial fibrillation recurrence in hypertensive patients.","volume":"47","author":"Fogari","year":"2006","journal-title":"J Cardiovasc Pharmacol"},{"key":"R23-1-20210208","first-page":"745","article-title":"Angiotensin receptor blockers and cardiac rhythm disorders.","volume":"99","author":"Galinier","year":"2006","journal-title":"Arch Mal Coeur Vaiss"},{"key":"R24-1-20210208","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/08037059209077502","article-title":"Prospective, randomizes, open-label, blinded end-point (PROBE) study: a novel design for intervention trials.","volume":"1","author":"Hansson","year":"1992","journal-title":"Blood Press"},{"key":"R25-1-20210208","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/eurheartj\/ehi668","article-title":"Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence.","volume":"27","author":"Ehrlich","year":"2005","journal-title":"Eur Heart J"},{"key":"R26-1-20210208","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1540-8167.2002.00801.x","article-title":"Aging-related increase to inducible atrial fibrillation in the rat model.","volume":"13","author":"Hayashi","year":"2002","journal-title":"J Cardiovasc Electrophysiol"},{"key":"R27-1-20210208","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/hrt.2003.015347","article-title":"Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease.","volume":"90","author":"Boldt","year":"2004","journal-title":"Heart"},{"key":"R28-1-20210208","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1161\/01.CIR.100.1.87","article-title":"Promotion of atrial fibrillation by heart failure in dogs: atrial remodelling of a different sort.","volume":"100","author":"Li","year":"1999","journal-title":"Circulation"},{"key":"R29-1-20210208","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/j.1540-8167.2006.00528.x","article-title":"What are arrhythmogenic substrates in diabetic rat atria?","volume":"17","author":"Kato","year":"2006","journal-title":"J Cardiovasc Electrophysiol"},{"key":"R30-1-20210208","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/01.CIR.104.3.286","article-title":"Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients.","volume":"104","author":"Lopez","year":"2001","journal-title":"Circulation"},{"key":"R31-1-20210208","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/01.CIR.0000137118.47943.5C","article-title":"Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis:results of randomized trial.","volume":"110","author":"Ciulla","year":"2004","journal-title":"Circulation"},{"key":"R32-1-20210208","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/hy0302.105683","article-title":"Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy. The Losartan Intervention for End-point reduction in hypertension (LIFE) study.","volume":"39","author":"Gerdts","year":"2002","journal-title":"Hypertension"},{"key":"R33-1-20210208","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0002-9149(02)02777-7","article-title":"Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA).","volume":"90","author":"Malmqvist","year":"2002","journal-title":"Am J Cardiol"},{"key":"R34-1-20210208","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0002-9343(03)00158-X","article-title":"A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension.","volume":"115","author":"Klingbeil","year":"2003","journal-title":"Am J Med"},{"key":"R35-1-20210208","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/01.CIR.0000141573.44737.5A","article-title":"Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol. The Losartan Intervention For End-point reduction in Hypertension (LIFE) trial.","volume":"110","author":"Devereux","year":"2004","journal-title":"Circulation"},{"key":"R37-1-20210208","doi-asserted-by":"crossref","first-page":"48231","DOI":"10.1074\/jbc.M405789200","article-title":"Angiotensin receptor type 1 forms a complex with the transient outward potassium channel Kv4.3 and regulates its gating properties and intracellular localization.","volume":"279","author":"Doronin","year":"2004","journal-title":"J Biol Chem"},{"key":"R38-1-20210208","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1161\/01.CIR.101.10.1199","article-title":"Losartan and its metabolite E3174 modify cardiac delayed rectifier K+ currents.","volume":"101","author":"Caballero","year":"2002","journal-title":"Circulation"},{"key":"R39-1-20210208","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.tips.2005.01.006","article-title":"Angiotensin II, angiotensin II antagonists and spironolactone and their modulation of cardiac repolarization.","volume":"26","author":"Delpon","year":"2005","journal-title":"Trends Pharmacol Sci"},{"key":"R40-1-20210208","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1161\/01.HYP.32.6.976","article-title":"Intracellular angiotensin II regulates the inward calcium current in cardiac myocytes.","volume":"32","author":"De Mello","year":"1998","journal-title":"Hypertension"},{"key":"R41-1-20210208","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1161\/01.CIR.100.21.2191","article-title":"The T-type Ca++ channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia induced atrial remodelling in dogs.","volume":"100","author":"Fareh","year":"1999","journal-title":"Circulation"},{"key":"R42-1-20210208","first-page":"643","article-title":"Effects of losartan on acute atrial electrical remodeling.","volume":"117","author":"Li","year":"2004","journal-title":"Chin Med J"},{"key":"R43-1-20210208","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1067\/mhj.2000.102901","article-title":"Neurohormonal modulation in cardiovascular disease.","volume":"139","author":"Unger","year":"2000","journal-title":"Am Heart J"}],"container-title":["Journal of Cardiovascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00005344-200803000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T21:44:02Z","timestamp":1618350242000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005344-200803000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/fjc.0b013e318160b42a","relation":{},"ISSN":["0160-2446"],"issn-type":[{"value":"0160-2446","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}